Clinical trials
Not yet recruiting Leukemia, Myeloid, Acute trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
154 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 3 |
| 2024 | 21 |
| 2025 | 25 |
| 2026 | 86 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Not yet recruiting | 154 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 12 |
| Ruijin Hospital | 6 |
| The First Affiliated Hospital of Soochow University | 6 |
| Assiut University | 5 |
| National Cancer Institute (NCI) | 4 |
| Peking University People's Hospital | 4 |
| Shenzhen Geno-Immune Medical Institute | 4 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 3 |
| M.D. Anderson Cancer Center | 3 |
| Nanfang Hospital, Southern Medical University | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 154 |
| Myelodysplastic Syndromes | 21 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 |
| Recurrence | 11 |
| Leukemia | 8 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 |
| Neoplasm, Residual | 5 |
| Anemia, Refractory, with Excess of Blasts | 4 |
| Hematologic Neoplasms | 4 |
| Burkitt Lymphoma | 3 |
Trials
Showing 51 to 75 of 154. Each trial links to its page on Pharma Observatory.
54 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.